Glenmark acquires Wockhardt's key OTC brands in US for undisclosed sum

Deal includes approved ANDAs for famotidine tablets, used in treatment and prevention of ulcers stomach and intestinal ulcers

Glenmark Pharmaceuticals
Sohini Das Mumbai
2 min read Last Updated : Jun 28 2022 | 3:32 PM IST
Mumbai-based Glenmark Pharmaceuticals said it has acquired the approved generic versions of certain over-the-counter drugs from Wockhardt Ltd in the US for an undisclosed sum. The move is expected to strengthen the acquirer's OTC presence in the US. 

The acquisition by the company's fully-owned subsidiary, Glenmark Pharmaceuticals Inc, USA, includes the approved abbreviated new drug applications (ANDAs) for famotidine tablets, 10 mg and 20 mg, used to treat and prevent ulcers in the stomach and intestine, the company said in a statement.

Glenmark did not disclose the financial details. The stock ended at Rs 387, up 0.8 per cent up on the BSE. 

"The over-the-counter market has long been an important segment of Glenmark's portfolio around the world. Our acquisition of these ANDAs represents the continued expansion of our business into the OTC market here in the United States and our commitment to ensuring patients have access to high quality, affordable medicines," Glenmark Pharmaceuticals Inc, USA, President Sanjeev Krishan said.

Glenmark has acquired ANDAs of anti-allergy medicine cetirizine hydrochloride tablets, acid reflux treatment drug Lansoprazole delayed-release capsules, and Olopatadine Hydrochloride Ophthalmic Solution for allergic conjunctivitis and allergic rhinitis, in the US.

The company said its current portfolio consists of 175 products authorised for distribution in the US market and 48 ANDAs pending approval with the USFDA.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Glenmark PharmaceuticalsWockhardtPharma CompaniesTabletshuman treatmentsStomach bugintestinal wormshealth newsIndian healthcarepharmacy

Next Story